In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Example Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Rigs to Reefs Habitat Protection 
Act''.

SEC. 2. DEFINITIONS.

    In this Act:
            (1) Decommissioning.--The term ``decommissioning'' includes 
        the flushing, plugging, and cementing of a platform.
            (2) Fund.--The term ``Fund'' means the Reef Maintenance 
        Fund established by section 3(h)(1).
            (3) Notice.--The term ``Notice'' means the notice to 
        lessees numbered 2010-G05, entitled ``Notice to Lessees and 
        Operators of Federal Oil and Gas Leases and Pipeline Right-of-
        Way Holders in the Outer Continental Shelf, Gulf of Mexico OCS 
        Region'', and issued September 15, 2010.
            (4) Platform.--The term ``platform'' means an offshore oil 
        and gas platform in the Gulf of Mexico that, as determined by 
        the Secretary--
                    (A) is no longer useful for operations, as defined 
                in the Notice; and
                    (B) has become critical for marine fisheries 
                habitat.
            (5) Program.--The term ``Program'' means the artificial 
        reef program authorized under the National Fishing Enhancement 
        Act of 1984 (33 U.S.C. 2101 et seq.).
            (6) Secretary.--The term ``Secretary'' means the Secretary 
        of the Interior.

SEC. 3. USE OF CERTAIN OFFSHORE OIL AND GAS PLATFORMS FOR ARTIFICIAL 
              REEFS.

    (a) Assessment.--As soon as practicable after the date of enactment 
of this Act, the Secretary shall conduct an assessment of each of the 
platforms--
            (1) to determine whether there are coral populations or 
        other protected species in the vicinity of the platform; and
            (2) to identify any species in the vicinity of the platform 
        that have recreational or commercial value.
    (b) Prohibition of Removal.--
            (1) In general.--Notwithstanding the Notice, no platforms 
        shall be removed in accordance with the Notice until the date 
        on which the Secretary has completed assessments of each of the 
        platforms under subsection (a).
            (2) Suspension of decommissioning.--If, during an 
        assessment conducted under subsection (a), the Secretary 
        determines that there is a substantial reef ecosystem in the 
        vicinity of the platform, the decommissioning of the platform 
        under the Notice shall be placed on hold until such time as the 
        Secretary determines that decommissioning the platform would 
        not harm the reef ecosystem.
    (c) Exemption From Certain Requirements.--The requirement in the 
Notice that a lessee remove a platform as soon as possible, but not 
later than 5 years after the effective date of the Notice or within 5 
years of the platform, meeting the definition of no longer useful for 
operations, whichever is later, shall not apply to a lessee that--
            (1) commits to entering the platform in the Program; and
            (2) demonstrates the commitment described in paragraph (1) 
        by initiating discussions with applicable States regarding 
        potential sites for the artificial reef.
    (d) Reefing in Place.--A lessee may, as appropriate, provide for 
reefing in place under the Program.
    (e) State Programs.--
            (1) In general.--A State that has a State rig-to-reef 
        program may enter into an agreement with any appropriate 
        entities to assume liability in Federal water for a structure 
        covered by the State program.
            (2) Maintenance.--Notwithstanding an agreement entered into 
        under paragraph (1), the operator of the covered structure 
        shall remain responsible for maintaining the covered structure.
    (f) Removal of Top Decks.--Under the Program, top decks of a rig 
may be removed, down to water surface level, if appropriate identifying 
markers are used to protect navigation.
    (g) Maintenance and Financial Requirements.--As a condition of 
inclusion in the Program, the owner of a rig enrolled in the Program 
shall be required to--
            (1) maintain an anode system for the rig; and
            (2) pay into the Fund an amount equal to 50 percent of the 
        estimated costs associated with the removal of the platform 
        that the owner would have been responsible for if the owner had 
        not participated in the Program, as determined by the 
        Secretary.
    (h) Reef Maintenance Fund.--
            (1) Establishment.--There is established in the Treasury of 
        the United States a fund to be known as the ``Reef Maintenance 
        Fund'', to be administered by the Secretary, to be available 
        without fiscal year limitation and not subject to 
        appropriation, for the maintenance of artificial reefs 
        established under the Program.
            (2) Transfers to fund.--The Fund shall consist of such 
        amounts deposited in the Fund under subsection (g)(2).
            (3) Prohibition.--Amounts in the Fund may not be made 
        available for any purpose other than a purpose described in 
        paragraph (1).
            (4) Annual reports.--
                    (A) In general.--Not later than 60 days after the 
                end of each fiscal year beginning with fiscal year 
                2012, the Secretary shall submit to the Committee on 
                Appropriations of the House of Representatives, the 
                Committee on Appropriations of the Senate, the 
                Committee on Energy and Natural Resources of the 
                Senate, and the Committee on Natural Resources of the 
                House of Representatives a report on the operation of 
                the Fund during the fiscal year.
                    (B) Contents.--Each report shall include, for the 
                fiscal year covered by the report, the following:
                            (i) A statement of the amounts deposited 
                        into the Fund.
                            (ii) A description of the expenditures made 
                        from the Fund for the fiscal year, including 
                        the purpose of the expenditures.
                            (iii) Recommendations for additional 
                        authorities to fulfill the purpose of the Fund.
                            (iv) A statement of the balance remaining 
                        in the Fund at the end of the fiscal year.
Example Output: Rigs to Reefs Habitat Protection Act - Directs the Secretary of the Interior to assess each offshore oil and gas platform in the Gulf of Mexico that is no longer useful for operations, and has become critical for a marine fisheries habitat, to: (1) determine whether there are coral populations or other protected species in the platform's vicinity, and (2) identify any species in the vicinity that have recreational or commercial value.

Prohibits the removal of any such platforms until the Secretary has completed each assessment.

Requires suspension of the decommissioning of a platform if a substantial reef ecosystem is in the vicinity until the Secretary determines that decommissioning would not harm the ecosystem.

Exempts from certain platform removal deadlines any lessees who: (1) commit to entering a particular platform in the artificial reef program under the National Fishing Enhancement Act of 1984, and (2) initiate discussions with applicable states regarding potential artificial reef sites.

Allows a lessee to provide for reefing in place under the artificial reef program.

Permits states with a state rig-to-reef program to enter agreements with any appropriate entities to assume liability in federal water for a structure covered by the state program.

Establishes a Reef Maintenance Fund. Requires the owner of a rig enrolled in the artificial reef program to: (1) maintain a rig anode system, and (2) pay into the Fund 50% of the estimated platform removal costs for which the owner would have been responsible if it had not participated in the program.

Example Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Climate Change Technology Deployment 
in Developing Countries Act of 2005''.

SEC. 2. CLIMATE CHANGE TECHNOLOGY DEPLOYMENT IN DEVELOPING COUNTRIES.

    Title VII of the Global Environmental Protection Assistance Act of 
1989 (Public Law 101-240; 103 Stat. 2521) is amending by adding at the 
end the following:

        ``PART C--TECHNOLOGY DEPLOYMENT IN DEVELOPING COUNTRIES

``SEC. 731. DEFINITIONS.

    ``In this part:
            ``(1) Carbon sequestration.--The term `carbon 
        sequestration' means the capture of carbon dioxide through 
        terrestrial, geological, biological, or other means, which 
        prevents the release of carbon dioxide into the atmosphere.
            ``(2) Greenhouse gas.--The term `greenhouse gas' means 
        carbon dioxide, methane, nitrous oxide, hydrofluorocarbons, 
        perfluorocarbons, and sulfur hexafluoride.
            ``(3) Greenhouse gas intensity.--The term `greenhouse gas 
        intensity' means the ratio of greenhouse gas emissions to 
        economic output.

``SEC. 732. REDUCTION OF GREENHOUSE GAS INTENSITY.

    ``(a) Lead Agency.--
            ``(1) In general.--The Department of State shall act as the 
        lead agency for integrating into United States foreign policy 
        the goal of reducing greenhouse gas intensity in developing 
        countries.
            ``(2) Reports.--
                    ``(A) In general.--Not later than 180 days after 
                the date of enactment of this part and each year 
                thereafter, the Secretary of State shall submit to the 
                appropriate authorizing and appropriating committees of 
                Congress a report on the 25 developing countries that 
                are the top energy users, including for each country a 
                description of--
                            ``(i) the quantity and types of energy 
                        used;
                            ``(ii) the greenhouse gas intensity of the 
                        energy, manufacturing, agricultural, and 
                        transportation sectors;
                            ``(iii) the progress of any projects 
                        undertaken to reduce greenhouse gas intensity;
                            ``(iv) the potential for further projects 
                        to reduce greenhouse gas intensity; and
                            ``(v) obstacles to the further reduction of 
                        greenhouse gas intensity.
                    ``(B) Use.--
                            ``(i) Initial report.--The Secretary of 
                        State shall use the initial report submitted 
                        under subparagraph (A) to establish baselines 
                        for the developing countries with respect to 
                        the information provided under clauses (i) and 
                        (ii) of that subparagraph.
                            ``(ii) Annual reports.--The Secretary of 
                        State shall use the annual reports submitted 
                        under subparagraph (A) to track the progress of 
                        the developing countries with respect to 
                        reducing greenhouse gas intensity.
    ``(b) Projects.--The Secretary of State, in coordination with 
Administrator of the United States Agency for International 
Development, shall (directly or through agreements with the World Bank, 
the International Monetary Fund, the Overseas Private Investment 
Corporation, and other development institutions) provide assistance to 
developing countries specifically for projects to reduce greenhouse gas 
intensity, including projects to--
            ``(1) leverage, through bilateral agreements, funds for 
        reduction of greenhouse gas intensity;
            ``(2) increase private investment in projects and 
        activities to reduce greenhouse gas intensity; and
            ``(3) expedite the deployment of technology to reduce 
        greenhouse gas intensity.
    ``(c) Focus.--In carrying out the projects, the Secretary of State 
shall focus on--
            ``(1) promoting the rule of law, property rights, contract 
        protection, and economic freedom; and
            ``(2) increasing capacity, infrastructure, and training.
    ``(d) Priority.--In carrying out the projects, the Secretary of 
State shall give priority to projects in the 25 developing countries 
identified in the report submitted under subsection (a)(2)(A).

``SEC. 733. TECHNOLOGY INVENTORY FOR DEVELOPING COUNTRIES.

    ``(a) In General.--The Secretary of State, in coordination with the 
Secretary of Energy, shall conduct an inventory of greenhouse gas 
intensity reducing technologies that are developed, or under 
development, to identify technologies that are suitable for transfer 
to, deployment in, and commercialization in the developing countries 
identified in the report submitted under section 732(a)(2)(A).
    ``(b) Report.--Not later than 180 days after the completion of the 
inventory under subsection (a), the Secretary of State and the 
Secretary of Energy shall jointly submit to Congress a report that--
            ``(1) includes the results of the completed inventory; and
            ``(2) identifies obstacles to the deployment of the 
        technologies studied.

``SEC. 734. TRADE-RELATED BARRIERS TO EXPORT OF GREENHOUSE GAS 
              INTENSITY REDUCING TECHNOLOGIES.

    ``Not later than 180 days after the date of enactment of this part, 
the United States Trade Representative shall--
            ``(1) identify trade-related barriers maintained by foreign 
        countries to the export of greenhouse gas intensity reducing 
        technologies and practices from the United States; and
            ``(2) negotiate with the foreign countries for the removal 
        of those barriers.

``SEC. 735. GREENHOUSE GAS INTENSITY REDUCING TECHNOLOGY EXPORT 
              INITIATIVE.

    ``(a) In General.--There is established an interagency working 
group to carry out a Greenhouse Gas Intensity Reducing Technology 
Export Initiative to--
            ``(1) promote the export of greenhouse gas intensity 
        reducing technologies and practices from the United States;
            ``(2) identify developing countries that should be 
        designated as priority countries for the purpose of exporting 
        greenhouse gas intensity reducing technologies and practices, 
        based on the report submitted under section 732(a)(2)(A);
            ``(3) identify potential barriers to adoption of exported 
        greenhouse gas intensity reducing technologies and practices; 
        and
            ``(4) identify previous efforts to export energy 
        technologies to learn best practices.
    ``(b) Composition.--The working group shall be composed of--
            ``(1) the Secretary of State, who shall act as the head of 
        the working group;
            ``(2) the Administrator of the United States Agency for 
        International Development;
            ``(3) the United States Trade Representative;
            ``(4) a designee of the Secretary of Energy; and
            ``(5) a designee of the Secretary of Commerce.
    ``(c) Performance Reviews and Reports.--Not later than 180 days 
after the date of enactment of this part and each year thereafter, the 
interagency working group shall--
            ``(1) conduct a performance review of actions taken and 
        results achieved by the Federal Government (including each of 
        the agencies represented on the interagency working group) to 
        promote the export of greenhouse gas intensity reducing 
        technologies and practices from the United States; and
            ``(2) submit to the appropriate authorizing and 
        appropriating committees of Congress a report that describes 
        the results of the performance reviews and evaluates progress 
        in promoting the export of greenhouse gas intensity reducing 
        technologies and practices from the United States, including 
        any recommendations for increasing the export of the 
        technologies and practices.

``SEC. 736. TECHNOLOGY STRATEGIC PLAN AND DEMONSTRATION PROJECTS.

    ``(a) In General.--The Secretary of State, in coordination with the 
Secretary of Energy and the Administrator of the United States Agency 
for International Development, shall develop a technology strategic 
plan, and carry out demonstration projects, to promote the adoption of 
technologies and practices that reduce greenhouse gas intensity in 
developing countries.
    ``(b) Demonstration Projects.--
            ``(1) In general.--The Secretaries and the Administrator 
        shall plan, coordinate, and carry out demonstration projects 
        under this section in at least 10 eligible countries, as 
        determined by the Secretaries and the Administrator.
            ``(2) Eligibility.--A country shall be eligible for 
        assistance under this subsection if the Secretaries and the 
        Administrator determine that the country has demonstrated a 
        commitment to--
                    ``(A) just and democratic governance, including--
                            ``(i) promoting political pluralism, 
                        equality, and the rule of law;
                            ``(ii) respecting human and civil rights;
                            ``(iii) protecting private property rights;
                            ``(iv) encouraging transparency and 
                        accountability of government; and
                            ``(v) combating corruption; and
                    ``(B) economic freedom, including economic policies 
                that--
                            ``(i) encourage citizens and firms to 
                        participate in global trade and international 
                        capital markets;
                            ``(ii) promote private sector growth and 
                        the sustainable management of natural 
                        resources;
                            ``(iii) strengthen market forces in the 
                        economy; and
                            ``(iv) respect worker rights.
            ``(3) Selection.--In determining which eligible countries 
        to provide funding to under paragraph (1), the Secretaries and 
        the Administrator shall consider--
                    ``(A) the extent to which the country meets or 
                exceeds the eligibility criteria;
                    ``(B) the opportunity to reduce greenhouse gas 
                intensity in the eligible country; and
                    ``(C) the opportunity to generate economic growth 
                in the eligible country.
            ``(4) Types of projects.--Demonstration projects under this 
        section may include--
                    ``(A) coal gasification, coal liquefaction, and 
                clean coal projects;
                    ``(B) carbon sequestration projects;
                    ``(C) cogeneration technology initiatives;
                    ``(D) renewable projects; and
                    ``(E) lower emission transportation.

``SEC. 737. FELLOWSHIP AND EXCHANGE PROGRAMS.

    ``The Secretary of State, in coordination with the Secretary of 
Energy, the Secretary of Commerce, and the Administrator of the 
Environmental Protection Agency, shall carry out fellowship and 
exchange programs under which officials from developing countries visit 
the United States to acquire expertise and knowledge of best practices 
to reduce greenhouse gas intensity in their countries.

``SEC. 738. AUTHORIZATION OF APPROPRIATIONS.

    ``There are authorized to be appropriated such sums as are 
necessary to carry out this part (other than section 736).

``SEC. 739. EFFECTIVE DATE.

    ``Except as otherwise provided in this part, this part takes effect 
on October 1, 2005.

``SEC. 740. TERMINATION OF AUTHORITY.

    ``The authority provided by this part terminates effective December 
31, 2010.''.
Example Output: Climate Change Technology Deployment in Developing Countries Act of 2005 - Amends the Global Environmental Protection Assistance Act of 1989 to consider the Department of State as the lead agency for integrating into U.S. foreign policy the goal of reducing greenhouse gas intensity in developing countries.

Directs the Secretary of State to: (1) provide assistance to developing countries to reduce greenhouse gas intensity; (2) inventory greenhouse gas intensity reducing technologies and identify appropriate technologies for developing countries; (3) develop a technology strategic plan and carry out demonstration projects in at least ten countries; and (4) carry out fellowship and exchange programs for officials from developing countries to acquire U.S. expertise in greenhouse gas intensity reduction practices.

Directs the U.S. Trade Representative to seek to eliminate foreign trade barriers to the export of U.S. greenhouse gas intensity reducing technologies and practices.

Establishes an interagency working group to carry out a greenhouse gas intensity reducing technology export initiative.

 Terminates programs under this Act as of December 31, 2010.

Example Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Preservation of Antibiotics for 
Medical Treatment Act of 2015''.

SEC. 2. FINDINGS.

    The Congress finds the following:
            (1) All uses of antibiotics, including for food-producing 
        animals, have the potential to cause resistance and contribute 
        to the development of antibiotic-resistant bacterial infections 
        in people.
            (2) In 1977, the Food and Drug Administration (FDA) 
        concluded that feeding livestock low doses of antibiotics used 
        in human disease treatment could promote the development of 
        antibiotic resistance in bacteria. However, the Food and Drug 
        Administration did not act in response to these findings, 
        despite laws requiring the agency to do so.
            (3) In 2012, the Food and Drug Administration Guidance for 
        Industry #209 provided a summary of over 40 years of peer-
        reviewed scientific literature regarding use of antimicrobial 
        drugs in livestock which reiterated that the use of antibiotics 
        in animals contributes to the resistance in human pathogens and 
        concludes that strategies for controlling antibiotic 
        resistance, including limiting medically important 
        antimicrobial drugs in food-producing animals only to uses that 
        are considered necessary for assuring animal health are needed.
            (4) The 2014 President's Council of Advisors on Science and 
        Technology Report to the President on Combating Antibiotic-
        Resistant Bacteria also concludes that substantial evidence 
        exists that the use of antibiotics in food animals promotes the 
        development and spread of antibiotic resistance in bacteria 
        that can spread to people and that it is clear that 
        agricultural use of antibiotics can affect human health.
            (5) Recently published scientific studies have shown that 
        food-producing animals, and animal production facilities, are a 
        source of antibiotic-resistant bacteria which have infected 
        humans and present an increased risk of acquiring and 
        antibiotics resistant infection.
            (6) Antibiotic resistance is a crisis which threatens 
        public health, the economy, and national security.
            (7) In 2013, the Centers for Disease Control and Prevention 
        estimated that antibiotic-resistant infections cause at least 2 
        million infections, 23,000 deaths, 8 million additional 
        hospital days, and $20 to $35 billion in excess direct health 
        care costs each year in the United States.
            (8) The 2014 World Health Organization report, 
        ``Antimicrobial Resistance: Global Report on Surveillance 
        2014'', concluded that antimicrobial resistance is a current 
        reality and the problem is so serious that it threatens the 
        achievements of modern medicine.
            (9) Without effective antibiotics--
                    (A) common infections could become untreatable--
                even fatal; and
                    (B) medical advances such as joint replacements, 
                Cesarean sections, organ transplants and chemotherapy 
                could become nonviable.
            (10) Antibiotic resistance, resulting in a reduced number 
        of effective antibiotics, may significantly impair the ability 
        of the United States to respond to terrorist attacks involving 
        bacterial infections, such as anthrax and smallpox, or to an 
        event resulting in a large influx of hospitalized patients.
            (11) In 2011, the Food and Drug Administration determined 
        that--
                    (A) 13.5 million kilograms of antibacterial drugs 
                were sold for use on food animals in the United States 
                in 2010;
                    (B) 3.3 million kilograms of antibacterial drugs 
                were used for human health in 2010; and
                    (C) therefore, 80 percent of antibacterial drugs 
                disseminated in the United States in 2010 were sold for 
                use on food animals, rather than being used for human 
                health.
            (12) The ``FDA Annual Summary Report on Antimicrobials Sold 
        or Distributed in 2012 for Use in Food-Producing Animals'' 
        showed that the use of medically important antibiotics in food-
        producing animals increased 16 percent from 2009 to 2012.
            (13)(A) In 2003, the Food and Drug Administration modified 
        the drug approval process for antibiotics to recognize the 
        development of resistant bacteria as an important aspect of 
        safety, but most antibiotics currently used in animal 
        production systems for nontherapeutic purposes were approved 
        before the Food and Drug Administration began considering 
        resistance during the drug-approval process.
            (B) The Food and Drug Administration has not established a 
        schedule for reviewing those existing approvals.
            (14) A stated goal of FDA Guidance documents 209 and 213 is 
        a reduction in the overall consumption of antibiotics. The FDA 
        policy continues to allow the use of antibiotics for routine 
        disease prevention without requiring evidence of the presence 
        of a specific disease or requiring the mitigation of conditions 
        which elevate disease risk.
            (15) There is inadequate distinction between usage for 
        disease prevention and production purposes, such as growth 
        promotion, on FDA approved drug labels. A 2014 analysis of the 
        approved animal drugs affected by Guidance 213 by the Pew 
        Charitable Trusts found that numerous approved drug labels 
        contained overlapping indications for growth-promotion and 
        disease prevention.
            (16) The European Union (EU) banned the use of antibiotics 
        for growth promotion in 2006, a full decade before the FDA's 
        voluntary approach will go into effect.
            (17) Since the EU ban, antibiotic usage has decreased 
        without affecting livestock production.
            (18) In 2010, the Danish Veterinary and Food Administration 
        testified that the Danish ban of the nontherapeutic use of 
        antibiotics in food-animal production resulted in a marked 
        reduction in antimicrobial resistance in multiple bacterial 
        species, including Campylobacter and Enterococci.
            (19) The experience in the Netherlands has shown that 
        during the phaseout use indications for growth promotion were 
        completely supplanted by disease prevention. Total antibiotic 
        consumption remained constant. After the implementation of 
        mandatory reduction targets and improved surveillance of usage 
        practices antibiotic consumption declined ahead of target 
        without impacting production levels.
            (20) In 2009, the Congressional Research Service concluded 
        that without restrictions on the use of antimicrobial drugs in 
        the production of livestock, export markets for livestock and 
        poultry could be negatively impacted due to restrictions on the 
        use of antibiotics in other nations.
            (21) The American Medical Association, the Infectious 
        Disease Society of America, the American Public Health 
        Association, the National Association of County and City Health 
        Officials, and the National Sustainable Agriculture Coalition 
        are among the over 400 organizations representing health, 
        consumer, agricultural, environmental, humane, and other 
        interests that have supported enactment of legislation to 
        phaseout nontherapeutic use in farm animals of medically 
        important antimicrobials.

SEC. 3. PURPOSE.

    The purpose of this Act is to preserve the effectiveness of 
medically important antimicrobials used in the treatment of human and 
animal diseases.

SEC. 4. PROOF OF SAFETY OF MEDICALLY IMPORTANT ANTIMICROBIALS.

    (a) Applications Pending or Submitted After Enactment.--Section 
512(d)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
360b(d)(1)) is amended--
            (1) in the first sentence--
                    (A) in subparagraph (H), by striking ``or'' at the 
                end;
                    (B) in subparagraph (I), by inserting ``or'' at the 
                end; and
                    (C) by inserting after subparagraph (I) the 
                following:
                    ``(J) with respect to a medically important 
                antimicrobial (as defined in subsection (q)), the 
                applicant has failed to demonstrate that there is a 
                reasonable certainty of no harm to human health due to 
                the development of antimicrobial resistance that is 
                attributable, in whole or in part, to the 
                nontherapeutic use (as defined in subsection (q)) of 
                the medically important antimicrobial or drug;''; and
            (2) in the second sentence, by striking ``(A) through (I)'' 
        and inserting ``(A) through (J)''.
    (b) Phased Elimination of Nontherapeutic Use in Animals of 
Medically Important Antimicrobials.--Section 512 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 360b) is amended by adding at the end 
the following:
    ``(q) Phased Elimination of Nontherapeutic Use in Animals of 
Medically Important Antimicrobials.--
            ``(1) Applicability.--This paragraph applies to the 
        nontherapeutic use in a food-producing animal of a drug--
                    ``(A) that is a medically important antimicrobial; 
                or
                    ``(B)(i) for which there is in effect an approval 
                of an application or an exemption under subsection (b), 
                (i), or (j) of section 505; or
                    ``(ii) that is otherwise marketed for human use.
            ``(2) Withdrawal.--The Secretary shall withdraw the 
        approval of a nontherapeutic use in food-producing animals of a 
        drug described in paragraph (1) on the date that is 2 years 
        after the date of enactment of this subsection unless--
                    ``(A) before the date that is 2 years after the 
                date of the enactment of this subsection, the Secretary 
                makes a final written determination that the holder of 
                the approved application has demonstrated that there is 
                a reasonable certainty of no harm to human health due 
                to the development of antimicrobial resistance that is 
                attributable in whole or in part to the nontherapeutic 
                use of the drug; or
                    ``(B) before the date specified in subparagraph 
                (A), the Secretary makes a final written determination 
                under this subsection, with respect to a risk analysis 
                of the drug conducted by the Secretary and other 
                relevant information, that there is a reasonable 
                certainty of no harm to human health due to the 
                development of antimicrobial resistance that is 
                attributable in whole or in part to the nontherapeutic 
                use of the drug.
            ``(3) Exemptions.--Except as provided in paragraph (5), if 
        the Secretary grants an exemption under section 505(i) for a 
        drug that is a medically important antimicrobial, the Secretary 
        shall rescind each approval of a nontherapeutic use in a food-
        producing animal of the medically important antimicrobial as of 
        the date that is 2 years after the date on which the Secretary 
        grants the exemption.
            ``(4) Approvals.--Except as provided in paragraph (5), if 
        an application for a drug that is a medically important 
        antimicrobial is submitted to the Secretary under section 
        505(b), the Secretary shall rescind each approval of a 
        nontherapeutic use in a food-producing animal of the medically 
        important antimicrobial as of the date that is 2 years after 
        the date on which the application is submitted to the 
        Secretary.
            ``(5) Exceptions.--Paragraph (3) or (4), as the case may 
        be, shall not apply if--
                    ``(A) before the date on which approval would be 
                rescinded under that paragraph, the Secretary makes a 
                final written determination that the holder of the 
                application for the approved nontherapeutic use has 
                demonstrated that there is a reasonable certainty of no 
                harm to human health due to the development of 
                antimicrobial resistance that is attributable in whole 
                or in part to the nontherapeutic use in the food-
                producing animal of the medically important 
                antimicrobial; or
                    ``(B) before the date specified in subparagraph 
                (A), the Secretary makes a final written determination, 
                with respect to a risk analysis of the medically 
                important antimicrobial conducted by the Secretary and 
                any other relevant information, that there is a 
                reasonable certainty of no harm to human health due to 
                the development of antimicrobial resistance that is 
                attributable in whole or in part to the nontherapeutic 
                use of the medically important antimicrobial.
            ``(6) Definition.--In this subsection:
                    ``(A) The term `medically important antimicrobial' 
                means a drug that--
                            ``(i) is intended for use in food-producing 
                        animals; and
                            ``(ii) is composed wholly or partly of--
                                    ``(I) any kind of penicillin, 
                                tetracycline, macrolide, lincosamide, 
                                streptogramin, aminoglycoside, 
                                sulfonamide, or cephalosporin; or
                                    ``(II) a drug from an antimicrobial 
                                class that is listed as `highly 
                                important', `critically important', or 
                                `important' by the World Health 
                                Organization in the latest edition of 
                                its publication entitled `Critically 
                                Important Antimicrobials for Human 
                                Medicine' (or a successor publication).
                    ``(B) The term `therapeutic use', with respect to a 
                medically important antimicrobial, means the use of 
                antimicrobials for the specific purpose of treating an 
                animal with a documented disease or infection. Such 
                term does not include the continued use of such an 
                antimicrobial in the animal after the disease or 
                infection is resolved.
                    ``(C) The term `nontherapeutic use'--
                            ``(i) means administration of antibiotics 
                        to an animal through feed and water (or, in 
                        poultry hatcheries, through any means) for 
                        purposes (such as growth promotion, feed 
                        efficiency, weight gain, or disease prevention) 
                        other than therapeutic use or nonroutine 
                        disease control; and
                            ``(ii) includes any repeated or regular 
                        pattern of use of medically important 
                        antimicrobials for purposes other than 
                        therapeutic use or nonroutine disease control.
                    ``(D) The term `noncustomary situation' does not 
                include normal or standard practice and conditions on 
                the premises that facilitate the transmission of 
                disease.
                    ``(E) The term `nonroutine disease control' means 
                the use of antibiotics on an animal that is not sick 
                but where it can be shown that a particular disease or 
                infection is present, or is likely to occur because of 
                a specific, noncustomary situation, on the premises at 
                the barn, house, pen, or other level at which the 
                animal is kept.''.

SEC. 5. LIMITATIONS ON USE OF MEDICALLY IMPORTANT ANTIMICROBIALS FOR 
              NONROUTINE DISEASE CONTROL.

    (a) Prohibited Acts.--Section 301 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 331) is amended by adding at the end the 
following:
    ``(ccc) The administration of a medically important antimicrobial 
to a food-producing animal for nonroutine disease control in violation 
of the requirements of section 512A.''.
    (b) Requirements.--Chapter V of the Federal Food, Drug, and 
Cosmetic Act is amended by inserting after section 512 of such Act (21 
U.S.C. 360b) the following:

``SEC. 512A. LIMITATIONS ON USE OF MEDICALLY IMPORTANT ANTIMICROBIALS 
              FOR NONROUTINE DISEASE CONTROL.

    ``(a) Prohibition.--It shall be unlawful to administer (including 
by means of animal feed) a medically important antimicrobial to a food-
producing animal for nonroutine disease control unless--
            ``(1) there is a significant risk that a disease or 
        infection present on the premises will be transmitted to the 
        food-producing animal;
            ``(2) the administration of the medically important 
        antimicrobial to the food-producing animal is necessary to 
        prevent or reduce the risk of transmission of the disease or 
        infection described in paragraph (1);
            ``(3) the medically important antimicrobial is administered 
        to the food-producing animal for nonroutine disease control for 
        the shortest duration possible to prevent or reduce the risk of 
        transmission of the disease or infection described in paragraph 
        (1) to the animal; and
            ``(4) the medically important antimicrobial is 
        administered--
                    ``(A) at a scale no greater than the barn, house, 
                or pen level; and
                    ``(B) to the fewest animals possible to prevent or 
                reduce the risk of transmission of the disease or 
                infection described in paragraph (1).
    ``(b) Definitions.--In this section:
            ``(1) The term `food-producing animal' means a food-
        producing animal intended for sale in interstate commerce.
            ``(2) The terms `medically important antimicrobial' and 
        `nonroutine disease control' have the meanings given to such 
        terms in section 512(q).''.
    (c) Applicability.--The amendments made by this section apply 
beginning on the date that is 6 months after the date of the enactment 
of this Act.
Example Output:
Preservation of Antibiotics for Medical Treatment Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to require an applicant for approval of a new animal drug that is a medically important antimicrobial to demonstrate that there is a reasonable certainty of no harm to human health from antimicrobial resistance attributable to the nontherapeutic use of the drug. Medically important antimicrobials are drugs intended for use in food-producing animals that contain: (1) specified antibiotics, or (2) certain drugs on the World Health Organization&rsquo;s list of critically important antimicrobials.  Two years after enactment of this Act, the Food and Drug Administration (FDA) must withdraw approval of a drug's nontherapeutic use in food-producing animals unless the FDA makes a determination that, based on the application holder's demonstration or an FDA risk analysis, there is a reasonable certainty of no harm to human health from antimicrobial resistance attributable to nontherapeutic use.  The FDA must rescind an exemption for investigational use of, or approval of a new drug application for, a medically important antimicrobial for its nontherapeutic use in food-producing animals two years after the exemption is granted or the application for approval is submitted unless there is a reasonable certainty of no harm to human health from antimicrobial resistance attributable to nontherapeutic use. A medically important antimicrobial cannot be administered (including through animal feed) to a food-producing animal for disease control unless there is a significant risk that a disease or infection present on the premises will be transmitted to the animal.